Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug curb alcohol cravings? new trial investigates

NCT ID NCT06817356

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether mazdutide, a drug given as a shot, can help people with alcohol use disorder drink less. About 308 participants will receive either mazdutide or a placebo for up to 36 weeks. The study measures changes in drinking behaviors using a standard questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mazdutide (a drug given as a shot)
What this could lead to
If it works, this could point toward a new medication to help people with alcohol use disorder drink less.
What could go wrong
This is an early proof-of-concept study, so it may not show a clear benefit. The drug might also have side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

308 people

The number who actually took part.

Started

Feb 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. Exclusion Criteria: * Have a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months. * Have initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment. * Have received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate. * Other protocol-specific inclusion and exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol use disorder

Contacts and locations

Locations

  • Adams Clinical

    Watertown, Massachusetts, 02472, United States

  • Ark Clinical Research - Fountain Valley

    Fountain Valley, California, 92708, United States

  • CenExel iResearch, LLC (CenExel iRA)

    Decatur, Georgia, 30030, United States

  • Clinical Neuroscience Solutions Inc

    Orlando, Florida, 32801, United States

  • Clinical Neuroscience Solutions Inc

    Memphis, Tennessee, 38119, United States

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801, United States

  • Dallas Clinical Research Center/Pillar Research

    Richardson, Texas, 75080, United States

  • Davis Clinical

    The Bronx, New York, 10461, United States

  • DelRicht Research

    Mandeville, Louisiana, 70471, United States

  • FutureSearch Trials of Dallas

    Dallas, Texas, 75251, United States

  • Headlands Research - Scottsdale

    Scottsdale, Arizona, 85260, United States

  • Headlands Research-Artemis San Diego

    San Diego, California, 92123, United States

  • Ichor Research

    Syracuse, New York, 13210, United States

  • K2 Medical Research

    Maitland, Florida, 32751, United States

  • K2 Medical Research - Maitland

    Maitland, Florida, 32751, United States

  • K2 Medical Research - Tampa

    Tampa, Florida, 33634, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Redbird Research LLC

    Las Vegas, Nevada, 89119, United States

  • Research Centers of America ( Hollywood )

    Hollywood, Florida, 33024, United States

  • Rhode Island Mood & Memory Research Institute

    East Providence, Rhode Island, 02914, United States

  • Richmond Behavioral Associates

    Staten Island, New York, 10314, United States

  • Summit Headlands

    Portland, Oregon, 97210, United States

  • Synergy San Diego

    Lemon Grove, California, 91945, United States

  • Vitalix Clinical

    Worcester, Massachusetts, 01608, United States

  • Woodland Resarch Northwest/ERG

    Rogers, Arkansas, 72758, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.